Results 51 to 60 of about 2,622 (185)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

Alimentary Pharmacology &Therapeutics, EarlyView.
This study provides real‐world evidence that implementing an advanced therapy care pathway for patients with IBD leads to significant healthcare cost savings without compromising quality of life. These findings support broader implementation of care pathways in the management of patients with chronic conditions to optimise care delivery and resource ...
Elyke H. Visser, Martijn. A. Oude Voshaar, Reinier C. A. van Linschoten, Alexander G. L. Bodelier, Claire Fitzpatrick, Vincent de Jonge, Hestia Vermeulen, K. Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C. Janneke van der Woude, R. L. West, D. van Noord   +12 more
wiley   +1 more source

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment

Immunological Medicine, 2023
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj   +1 more source

Filgotinib for treating moderate to severe rheumatoid arthritis [PDF]

Prescriber, 2021
Filgotinib (Jyseleca) is a new oral janus kinase (JAK) inhibitor that has recently been approved by NICE for moderate or severe rheumatoid arthritis after failure of other disease‐modifying antirheumatic drugs (DMARDs). This article discusses its efficacy, side‐effects and place in therapy.
openaire   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. [PDF]

, 2023
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca(®)), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness and cost effectiveness of ...
Asselt, A.D. van, McDermott, Kevin, Hoentjen, Frank, Peeters, A., Kimman, M., Armstrong, N., van Asselt, A.D.I., van Asselt, Antoinette D.I.; id_orcid, Kimman, Merel, van Asselt, Antoinette D.I., Armstrong, Nigel, Grimm, S.E., Ahmadu, Charlotte, Stirk, L., Hoentjen, F., Ahmadu, C., Grimm, Sabine E., Joore, Manuela A., Govers, Tim M., Stirk, Lisa, Govers, T.M., Joore, M.A.; id_orcid, McDermott, K., Peeters, Andrea   +23 more
core   +1 more source

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE [PDF]

, 2023
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long-term ...
Zhou, Yan, Maaser, Christian; https://orcid.org/, Schreiber, Stefan; https://orcid.org/, Moerch, Ulrik, Vermeire, Séverine; https://orcid.org/, Hsieh, Jeremy, Van Hoek, Paul, Oortwijn, Alessandra; https://orcid.org/, de Haas, Angela, Loftus, Edward V; https://orcid.org/, Watanabe, Mamoru; https://orcid.org/, Rogler, Gerhard; https://orcid.org/, Danese, Silvio; https://orcid.org/, Rudolph, Christine, Faes, Margaux   +14 more
core   +1 more source

Successful treatment of rheumatoid arthritis‐associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition

Respirology Case Reports
Filgotinib, a janus kinase 1 (JAK1) inhibitor, is used in the treatment of rheumatoid arthritis (RA). RA‐associated interstitial lung disease (RA‐ILD) is a severe RA complication with no established effective treatment.
Atsuhiko Sunaga, Takuya Inoue
doaj   +1 more source